About Iovance Biotherapeutics
Iovance Biotherapeutics is a company based in San Carlos (United States) founded in 2007 by Robert T Brooke. It operates as a HealthTech. The company has 838 employees. Iovance Biotherapeutics has completed 1 acquisition, including Proleukin. Iovance Biotherapeutics offers products and services including Amtagvi and Proleukin. Iovance Biotherapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, Revolution Medicines, Blueprint Medicines, Syndax and C4 Therapeutics, among others.
- Headquarter San Carlos, United States
- Employees 838
- Founders Robert T Brooke
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website iovance.com
- Social LinkedIn X
- Legal Name Iovance Biotherapeutics, Inc.
Products & Services of Iovance Biotherapeutics
Iovance Biotherapeutics offers a comprehensive portfolio of products and services, including Amtagvi and Proleukin.
Amtagvi is developed for advanced cancer treatment therapies.
Proleukin is utilized in cancer immunotherapy treatment solutions.
Funding Insights of Iovance Biotherapeutics
- Total Rounds 11
- Last Round Post-IPO — $100M
- First Round $500,000
(Sep 2010)
- Investors Count 3
Latest 10 of 11 funding rounds of Iovance Biotherapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2016 | $100M | Post-IPO | – | – | – |
| Jun 2016 | $100M | Post-IPO | – | – | |
| Jun 2016 | – | Post-IPO | – | – | |
| Nov 2014 | $23.29M | Post-IPO | – | – | – |
| Nov 2013 | $23.3M | Post-IPO | – | – | |
| May 2013 | $1.35M | Post-IPO | – | – | – |
| Jul 2011 | $5M | Post-IPO | – | – | – |
| Apr 2011 | $500,000 | Post-IPO | – | – | – |
| Dec 2010 | $640,000 | Post-IPO | – | – | – |
| Oct 2010 | $250,000 | Post-IPO | – | – | – |
3 investors in total: 3 institutional.
Investors in Iovance Biotherapeutics
Iovance Biotherapeutics has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Orbimed, Frazier Healthcare Partners and Perceptive Advisors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare sector private equity investments are managed by the firm. | 1991 | frazierhealthcare.com | Seattle, United States | |
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States |
Investor details for Iovance Biotherapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Iovance Biotherapeutics
90 people are tracked at Iovance Biotherapeutics (51 in leadership, 6 in board & advisors, 33 in team); the tracked headcount is 838.
| Name | Role | Group |
|---|---|---|
Robert T Brooke | Founder & CEO | Leadership |
Anthonius Kley | Associate Director Facilities Engineering | Leadership |
Katie Benson | Senior Director, Global Customer Engagement & Strategic Alliances | Leadership |
Howard B. Johnson | Chief Business Officer | Leadership |
Igor Bilinsky | COO | Leadership |
Toby S. | Director; Global Channel Management | Leadership |
Gurinder Bhatia | VP Of Infrastructure & Operations | Leadership |
Balaji Hariharan | Director Infrastructure Operations | Leadership |
Amit Joshi | Senior Director, Strategic Sourcing | Leadership |
Dan Kirby | Chief Commercial Officer (cco) | Leadership |
Minjie Feng | Senior Director | Leadership |
Morgan Landes | Director, Life Cycle Program Management | Leadership |
Brian Shew | SVP, Head of Digital & Information Technology | Leadership |
Leah Robinson | Director, Logistics And Planning | Leadership |
Katrina Bezak | Senior Director, Commercial Operations | Leadership |
Rana Fiaz M.d. | Executive Director | Leadership |
Bill Hershfield | Head Of Market Access Operations, Distribution And Pricing | Leadership |
Frederick G. Vogt | Interim CEO, President & General Counsel | Leadership |
Allison Marotta | Director, Supply Chain | Leadership |
Jim Meyer | Vice President Global Commercial | Leadership |
70 more people are available in the full profile.
Complete people profiles for Iovance Biotherapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Iovance Biotherapeutics
Iovance Biotherapeutics is a publicly listed company on the NASDAQ with ticker symbol IOVA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date27 May 2010
- Listed onNASDAQ: IOVA
- Listed entityIovance Biotherapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS4622601007
- Share price$14.62 (+9.84% on the day) · 2026-10-09
- Market capitalisation$6.62B
- EPS (diluted, trailing year)$-0.72
- Volume (last session)16,990,348
Financials of Iovance Biotherapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $263.5M | -$391.0M | -$350.9M |
| 2024 | $164.1M | -$372.2M | -$351.7M |
| 2023 | $1.2M | -$444.0M | -$427.4M |
| 2022 | – | -$395.9M | -$377.7M |
| 2021 | – | -$342.2M | -$328.7M |
Detailed financial statements for Iovance Biotherapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Iovance Biotherapeutics
Iovance Biotherapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Proleukin.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Information on cancer drugs is provided via an online platform. | proleukin.com | Yardley, United States | 1998 | Jan 2023 | •••• |
Complete acquisition details for Iovance Biotherapeutics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Iovance Biotherapeutics
5 dated milestones of Iovance Biotherapeutics across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Iovance Biotherapeutics is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $500K.
- Funding Latest funding round, Post-IPO, of $100.0M.
- Acquisition Acquires Proleukin.
Competitors of Iovance Biotherapeutics
Iovance Biotherapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Revolution Medicines, Blueprint Medicines, Syndax and C4 Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| blueprintmedicines.com | 2008 | Cambridge, United States | $115M | 201 | Selective kinase inhibitors are developed for genomically defined cancers. | |
| syndax.com | 2005 | Waltham, United States | $198.29M | 107 | Targeted therapies for cancer treatment are developed. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| mereobiopharma.com | 2015 | London, United Kingdom | $119M | 56 | Therapeutics for cancer and rare diseases are developed. | |
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| argenx.com | 2008 | Ghent, Belgium | $61.9M | 355 | Antibody-based drugs are developed for autoimmune diseases and cancer treatment. |
Detailed competitors of Iovance Biotherapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Iovance Biotherapeutics
The website of Iovance Biotherapeutics (iovance.com) receives about 16.2K visits a month and ranks #1,264,131 among all websites worldwide, #1,606 in Biotechnology and Pharmaceuticals.
- Monthly visits16.2K
▼ 19.8% vs previous month
- Unique visitors9K
per month
- Global rank#1,264,131
among all websites
- Category rank#1,606
Health · Biotechnology and Pharmaceuticals
- Bounce rate42%
- Pages per visit2.0
- Average visit56 sec
- DevicesDesktop 44% · Mobile 56%
Websites whose visitors overlap most with Iovance Biotherapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| maxcyte.com | 100% | 11.2K | #1,958,980 | View details | |
| fiercebiotech.com | 81% | 858.3K | #81,022 | View details | |
regmednet.com | regmednet.com | 74% | – | #1,456,222 | – |
| lilly.com | 60% | 4.9M | #13,252 | View details | |
drugs.com | drugs.com | 60% | – | #3,085 | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 8 similar websites and full traffic analytics for Iovance Biotherapeutics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 8 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Iovance Biotherapeutics
Complete news archive for Iovance Biotherapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Iovance Biotherapeutics
10 companies that operate in the same segment as Iovance Biotherapeutics (Cell Therapy), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 300 | |
T-cell-based immunotherapies for cancer treatment are developed. | 2000 | Tubingen, Baden-wurttemberg, Germany | USD 236.4 M | USD 54.47 M | 423 | |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases. | 2015 | London, England, United Kingdom | USD 181.37 M | USD 75.56 M | 647 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 194 | |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment | 2015 | Cambridge, Massachusetts, United States | USD 158 M | – | 58 | |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | 2011 | San Francisco, California, United States | USD 36.13 M | – | 36 | |
Developer of immune cell therapies | 2019 | San Francisco, California, United States | USD 631.16 M | – | 178 | |
Cue Biopharma is focused on developing immunotherapy solutions. | 2015 | Cambridge, Massachusetts, United States | USD 10 M | USD 27.47 M | 41 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Iovance Biotherapeutics
Iovance Biotherapeutics was founded in 2007 and raised its 1st funding round 3 years after it was founded.
Iovance Biotherapeutics is headquartered in San Carlos, United States. It is registered at San Carlos, California, United States.
Robert T Brooke is the current CEO of Iovance Biotherapeutics. They have also founded this company.
Iovance Biotherapeutics has 838 employees.
Annual revenue of Iovance Biotherapeutics is $263.5M as on Dec 31, 2025.
Iovance Biotherapeutics is engaged in pioneering cancer treatment by leveraging the human immune system. The company is dedicated to developing Tumor Infiltrating Lymphocyte (TIL) therapies and Peripheral Blood Lymphocyte (PBL) therapies for solid tumors and blood cancers. Solutions are personalized to target diverse cancer cells unique to each patient. Research and clinical trials are conducted across multiple advanced cancer types, including melanoma, NSCLC, and endometrial cancer. Manufacturing is supported by a state-of-the-art facility in Philadelphia. The focus is placed on next-generation approaches to enhance cancer treatment outcomes.
Iovance Biotherapeutics's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and argenx.
Iovance Biotherapeutics offers Amtagvi and Proleukin.
Yes, Iovance Biotherapeutics is publicly traded on NASDAQ under the ticker symbol IOVA.
Iovance Biotherapeutics has made 1 acquisition, including Proleukin.
Iovance Biotherapeutics has 3 investors. Key investors include Orbimed, Frazier Healthcare Partners, and Perceptive Advisors.
Iovance Biotherapeutics operates through Iovance Biotherapeutics, Inc..